Nautilus Biotechnolgy Statistics
Want to see NAUT full AI Analyst Report?
Nautilus Biotechnolgy (NAUT) Stock Statistics & Valuation Metrics
Total Valuation
Nautilus Biotechnolgy has a market cap or net worth of $284.04M. The enterprise value is $120.84M.
- Market Cap
- $284.04M
- Enterprise Value
- $120.84M
Share Statistics
Nautilus Biotechnolgy has 127,372,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 127,372,420
- Owned by Insiders
- 45.16%
- Owned by Institutions
- 9.96%
Financial Efficiency
Nautilus Biotechnolgy’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -35.74%.
- Return on Equity (ROE)
- -0.38
- Return on Assets (ROA)
- -0.31
- Return on Invested Capital (ROIC)
- -35.74%
- Return on Capital Employed (ROCE)
- -0.36
- Revenue Per Employee
- 0
- Profits Per Employee
- -460.95K
- Employee Count
- 128
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Nautilus Biotechnolgy is -5.04. Nautilus Biotechnolgy’s PEG ratio is -0.62.
- PE Ratio
- -5.04
- PS Ratio
- 696.94
- PB Ratio
- 2.53
- Price to FCF
- -5.36
- Price to Operating Cash Flow
- -5.62
- PEG Ratio
- -0.62
Income Statement
In the last 12 months, Nautilus Biotechnolgy had revenue of 0 and earned -59.00M in profits. Earnings per share was -0.47.
- Revenue
- 0
- Gross Profit
- -6.46M
- Operating Income
- -66.84M
- Pretax Income
- -59.00M
- Net Income
- -59.00M
- EBITDA
- -52.54M
- Earnings Per Share (EPS)
- -0.47
Cash Flow
In the last 12 months, operating cash flow was -52.48M and capital expenditures -2.65M, giving a free cash flow of -55.13M billion.
- Operating Cash Flow
- -52.48M
- Free Cash Flow
- -55.13M
- Free Cash Flow per Share
- -0.43
Dividends & Yields
Nautilus Biotechnolgy pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -19.16%
- Earnings Yield
- -20.37%
Stock Price Statistics
- Beta
- 0.96
- 52-Week Price Change
- 47.68%
- 50-Day Moving Average
- 1.73
- 200-Day Moving Average
- 2.12
- Relative Strength Index (RSI)
- 49.41
- Average Volume (3m)
- 5.79M
Important Dates
Nautilus Biotechnolgy upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Nautilus Biotechnolgy as a current ratio of 13.33, with Debt / Equity ratio of 19.12%
- Current Ratio
- 13.33
- Quick Ratio
- 13.33
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.34
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Nautilus Biotechnolgy has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Nautilus Biotechnolgy EV to EBITDA ratio is -5.61, with an EV/FCF ratio of -5.52.
- EV to Sales
- 717.24
- EV to EBITDA
- -5.61
- EV to Free Cash Flow
- -5.52
- EV to Operating Cash Flow
- -5.79
Balance Sheet
Nautilus Biotechnolgy has $86.58M in cash and marketable securities with $26.74M in debt, giving a net cash position of $59.84M billion.
- Cash & Marketable Securities
- $86.58M
- Total Debt
- $26.74M
- Net Cash
- $59.84M
- Net Cash Per Share
- $0.47
- Tangible Book Value Per Share
- $0.92
Margins
Gross margin is -362.50%, with operating margin of -15105.66%, and net profit margin of -13816.75%.
- Gross Margin
- -362.50%
- Operating Margin
- -15105.66%
- Pretax Margin
- -13816.75%
- Net Profit Margin
- -13816.75%
- EBITDA Margin
- -12788.92%
- EBIT Margin
- -14121.93%
Analyst Forecast
The average price target for Nautilus Biotechnolgy is $4.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $4.00
- Price Target Upside
- 79.37% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 7.31%
Scores
- Smart Score
- 7
- AI Score
- 52
